ORIAHNN (COPACKAGED) (elagolix and estradiol and norethisterone) by AbbVie is estradiol/norethindrone acetate (e2/neta), a combination of estrogen and progestin. Approved for heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. First approved in 2020.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
ORIAHNN is a copackaged oral combination of elagolix (a GnRH receptor antagonist) with estradiol and norethisterone acetate, designed to treat heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Elagolix suppresses LH and FSH to reduce ovarian hormone production and bleeding, while the estradiol and progestin add-back protects bone density and endometrial health. This triple-mechanism approach addresses both the disease symptom and the hormonal side effects of GnRH antagonism alone.
ORIAHNN is in peak commercial phase with strong patent protection through 2040, supporting stable brand team investment and marketing initiatives.
estradiol/norethindrone acetate (E2/NETA), a combination of estrogen and progestin. Elagolix is a GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of elagolix results in dose-dependent suppression of…
Worked on ORIAHNN (COPACKAGED) at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moORIAHNN currently shows zero linked job postings in the dataset, suggesting limited active hiring; however, opportunities exist in brand management, field sales, medical affairs, and market access roles typical of a peak-lifecycle marketed product. Career growth on this product is steady but measured, with emphasis on maximizing market penetration rather than launching new indications.